Centene venetoclax Coverage & Prior Auth Update

Coverage Criteria

Initial Therapy — CLL/SLL

Covered when ALL of the following are met for CLL or SLL:

CLL/SLL initial: 1. Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); 2. Prescribed by or in consultation with an oncologist or hematologist; 3. Age ≥ 18 years; 4. For brand Venclexta requests, member must use generic venetoclax if available unless contraindicated or clinically significant adverse effects are experienced; 5. Request is either (a) prescribed as first-line therapy or for relapse if previously used as first-line therapy in combination with obinutuzumab (Gazyva), or (b) prescribed as subsequent therapy for relapsed/refractory disease as single agent or in combination with rituximab or obinutuzumab; 6. Dose does not exceed 400 mg per day (4 tablets) unless supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence);dose limits: 400 mg/day; 4 tablets/day

Prescribed regimen must be FDA-approved or recommended by NCCN.

Initial Therapy — Myeloid Leukemias

Covered when ALL of the following are met for myeloid leukemias:

Myeloid initial: 1. Diagnosis of acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN); 2. Prescribed by or in consultation with an oncologist or hematologist; 3. Age ≥ 18 years; 4. For brand Venclexta requests, member must use generic venetoclax if available unless contraindicated or clinically significant adverse effects are experienced; 5. If AML: disease is newly diagnosed and (a) age > 60 years or (b) member is not a candidate for or declines intensive induction chemotherapy, or disease has relapsed/refractory to induction therapy; 6. If BPDCN: disease is systemic and request is for palliative treatment for patients not candidates for intensive remission therapy, or disease is relapsed/refractory; 7. When used in combination regimens: in combination with azacitidine or decitabine, dose does not exceed 400 mg/day (4 tablets); in combination with low-dose cytarabine, dose does not exceed 600 mg/day (6 tablets); alternative dosing must be supported by practice guidelines or peer-reviewed literature (prescriber must submit evidence); 8. Prescribed regimen must be FDA-approved or recommended by NCCN;400 mg/day with azacitidine/decitabine; 600 mg/day with low-dose cytarabine

Prior authorization may be required; regimen-specific dosing per prescribing information.

Initial Therapy — Mantle Cell Lymphoma (off-label)

Covered off-label for mantle cell lymphoma when ALL of the following are met:

Mantle cell lymphoma: 1. Diagnosis of mantle cell lymphoma; 2. Prescribed by or in consultation with an oncologist or hematologist; 3. Age ≥ 18 years; 4. For brand Venclexta requests, member must use generic venetoclax if available unless contraindicated or clinically significant adverse effects are experienced; 5. Venclexta is prescribed as one of the following: single-agent subsequent therapy; subsequent therapy in combination with rituximab or ibrutinib (Imbruvica); or in combination with obinutuzumab (Gazyva) and ibrutinib when TP53 mutation positive and a clinical trial is not available (a clinical trial is strongly recommended); 6. Dose is within FDA maximum limits for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence);

Prescribed regimen must be FDA-approved or recommended by NCCN.

Initial Therapy — Multiple Myeloma (off-label)

Covered off-label for multiple myeloma with t(11;14) when ALL of the following are met:

Multiple myeloma t(11;14): 1. Diagnosis of multiple myeloma with t(11;14) translocation; 2. Prescribed by or in consultation with an oncologist or hematologist; 3. Age ≥ 18 years; 4. Member has received at least one prior therapy; 5. Prescribed in combination with dexamethasone; 6. For brand Venclexta requests, member must use generic venetoclax if available unless contraindicated or clinically significant adverse effects are experienced; 7. Dose is within FDA maximum limits or is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence);

Prior authorization may be required; prescribed regimen must be FDA-approved or recommended by NCCN.

Initial Therapy — Additional NCCN Recommended Uses (off-label)

Covered for select additional NCCN-recommended off-label uses when ALL are met:

NCCN recommended uses: 1. Diagnosis is one of the specified NCCN-recommended conditions (examples include: CMML-2 with venetoclax + hypomethylating agents; relapsed/refractory hairy cell leukemia; pediatric relapsed/refractory ALL; myeloproliferative neoplasm with venetoclax + HMA; systemic light chain amyloidosis relapsed/refractory; Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma as single agent); 2. Prescribed by or in consultation with an oncologist or hematologist; 3. For non-pediatric ALL uses: age ≥ 18 years unless specified otherwise; 4. Member has received prior therapy where required by the indication (see Appendix B examples); 5. For brand Venclexta requests, member must use generic venetoclax if available unless contraindicated or clinically significant adverse effects are experienced; 6. Dose is within FDA maximum limits or is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence);

Prior authorization may be required; prescribed regimen must be FDA-approved or recommended by NCCN.

Continuation of Therapy

Covered when ALL of the following are met for continuation:

Continued therapy general: 1. Member is currently receiving venetoclax via Centene benefit or documentation supports member has received venetoclax for at least 30 days; 2. Member is responding positively to therapy; 3. Regimen and dose remain within specified limits or are supported by practice guidelines or peer-reviewed literature (prescriber must submit evidence); 4. For AML, continued therapy must be in combination with azacitidine, decitabine, or low-dose (20 mg/m2) cytarabine; 5. For brand Venclexta requests, generic venetoclax must be used if available unless contraindicated or clinically significant adverse effects are experienced; 6. If request is for a dose increase, new dose must not exceed applicable limits (e.g., 400 mg/day for CLL/SLL and AML with azacitidine/decitabine; 600 mg/day with low-dose cytarabine) or must be supported by guidelines/literature (prescriber must submit supporting evidence).

Prior authorization may be required; duration limits per line of business.

Indications

Covered when criteria below are met per indication and supporting documentation:

Covered indications (FDA or NCCN-supported off-label): Coverage allowed for FDA-approved indications (e.g., CLL/SLL; AML in combination with azacitidine, decitabine, or low-dose cytarabine) and select NCCN-supported off-label indications (including systemic light chain amyloidosis, Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, BPDCN, mantle cell lymphoma scenarios, CMML-2, hairy cell leukemia, pediatric ALL);

Documentation must support the specific indication and follow indication-specific dosing and prior authorization requirements.

Dosing

Dosing and administration conditions required for coverage:

Dosing requirements: 1. Appropriate ramp-up schedule is required (5-week ramp-up for CLL/SLL and monotherapy per prescribing information); 2. Maintenance dosing examples: CLL/SLL maintenance target 400 mg orally once daily after ramp-up; AML combinations: up-titration to 400 mg/day in combination with azacitidine or decitabine, or up to 600 mg/day with low-dose cytarabine as specified by regimen; 3. Dose must not exceed applicable maximums (400 mg/day or 600 mg/day) unless supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence); 4. Follow prescribing information for timing with combination agents (e.g., initiation in Cycle 1 Day 22 when given with obinutuzumab per regimen-specific guidance).5-week ramp-up; 400 mg/day; 600 mg/day

Follow product labeling and NCCN-recommended schedules.

Contraindications / Safety

Safety and contraindications affecting coverage:

Contraindications at initiation: Do not initiate venetoclax concomitantly with strong CYP3A inhibitors during initiation and ramp-up in patients with CLL/SLL; such concomitant use is a contraindication and requests may be denied;

See Appendix C for contraindication detail.

AML eligibility

AML eligibility considerations:

AML intensive induction eligibility: Coverage for AML combinations no longer requires medical justification that the member is unable to receive intensive induction chemotherapy; NCCN supports acceptance of member decline or general ineligibility as adequate justification;

Operational change documented in 4Q 2024 review.

Non‑FDA approved indications that are not specifically listed in this policy are not authorized unless the provider supplies sufficient documentation of efficacy and safety consistent with the applicable Centene off‑label use policies (see CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace, and CP.PMN.53 for Medicaid).

Requests for therapy for non‑FDA approved indications that lack adequate supporting documentation per the off‑label use policies will not be authorized. Providers must submit evidence (e.g., guideline recommendations, peer‑reviewed literature, or an evidence of coverage document) demonstrating clinical benefit and safety for the requested off‑label use.

When a requested use is not listed in this policy but does not fall under the formulary/no‑coverage rules, the request will be evaluated under Centene’s applicable off‑label use policy. Prior authorization for such off‑label requests requires documentation that aligns with the off‑label policy referenced for the member’s line of business (CP.CPA.09, HIM.PA.154, or CP.PMN.53) and any evidence or guidelines supporting the regimen.

Venetoclax should not be initiated concomitantly with strong CYP3A inhibitors during initiation and the ramp‑up period for patients with CLL/SLL. Concomitant use in this setting is listed as a contraindication and such requests may be denied.

Initial Therapy Criteria

Initial therapy — criteria differ by diagnosis (CLL/SLL, myeloid leukemias, mantle cell lymphoma, multiple myeloma, etc.)

Initial coverage criteria differ by diagnosis; see the diagnosis-specific sets below:

Initial therapy grouped: See and apply the specific initial therapy criteria for each diagnosis: CLL/SLL; AML and BPDCN; mantle cell lymphoma (off-label); multiple myeloma with t(11;14) (off-label); and additional NCCN-recommended off-label uses. Common requirements across diagnoses include prescriber specialty (oncologist/hematologist or consultation), age criteria, preference for generic venetoclax for brand requests, prescriber evidence if using off-label dosing, and regimen must be FDA-approved or recommended by NCCN.

Refer to each indication-specific initial therapy criteria for exact requirements.

Initial therapy — Initial dosing and ramp-up

Initial dosing and ramp-up

Ramp-up schedule: Initiate venetoclax using the recommended 5-week ramp-up schedule (example: 20 mg PO QD week 1, 50 mg PO QD week 2, with escalation to target maintenance dosing per indication); follow product labeling for exact weekly titration and any regimen-specific timing (e.g., start timing when combined with obinutuzumab per regimen guidance).

Continuation Therapy Criteria

Continuation therapy — Criteria for continued venetoclax coverage

Criteria for continued venetoclax coverage:

Continued therapy nodes: 1. Member has been receiving venetoclax for at least 30 days or is currently receiving via Centene benefit; 2. Member is responding positively to therapy; 3. Regimen and dose remain within specified limits or are supported by practice guidelines/peer-reviewed literature (prescriber must submit evidence); 4. For AML, continued use must be in combination with azacitidine, decitabine, or low-dose cytarabine; 5. For brand Venclexta requests, generic venetoclax must be used if available unless contraindicated or clinically significant adverse effects are experienced;

Prior authorization may be required; documentation must support ongoing benefit.

Continuation therapy — Continued therapy conditions

Continued therapy conditions

Continuation after ramp-up: Continue maintenance dosing (for example, 400 mg QD for CLL/SLL) until disease progression or unacceptable toxicity; in combination regimens, continue per regimen-specific durations (e.g., Venclexta with rituximab: continue venetoclax 400 mg QD for 24 months from Cycle 1 Day 1 of rituximab; Venclexta with obinutuzumab: continue per cycle guidance), and any dose increase requests must meet applicable maximums or be supported by guidelines/literature.

Provider Actions & Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required. Document the diagnosis, prescriber specialty (oncologist or hematologist), patient age, and that the requested regimen meets the applicable indication criteria. Failure to submit required documentation that matches the policy criteria may result in denial.

Prescriber must be an oncologist or hematologist or consult with one.
Age eligibility (typically ≥18 years) must be documented.
Diagnosis must match an approved indication per the policy (e.g., CLL, SLL, AML, BPDCN, mantle cell lymphoma, multiple myeloma with t(11;14), or other NCCN-supported off‑label indications).

Denial Risk

Non‑FDA Indications — Documentation and Evidence Required

Requests for non‑FDA (off‑label) indications will be considered only when the prescriber provides sufficient supporting documentation of efficacy and safety per the applicable off‑label use policies (e.g., CP.CPA.09, HIM.PA.154, CP.PMN.53) or when the regimen is recommended by NCCN. The prescriber must submit relevant peer‑reviewed literature or guideline references to support the off‑label dose and regimen.

Coding & Product Information

Drug codes / availabilityNDC | mixed

NDCs not listed

Document references prescribing information but does not list NDCs

Maximum dosing thresholds

CLL/SLL and AML (with azacitidine or decitabine)Maximum dosing threshold: 400 mg per day (4 tablets).

AML (with low-dose cytarabine)Maximum dosing threshold: 600 mg per day (6 tablets).

Dose adjustmentsAny dose above these thresholds must be supported by clinical practice guidelines or peer-reviewed literature with prescriber evidence.

Step Therapy / Substitution

Requirement	Details
Generic substitution preference	For brand Venclexta requests, member must use generic venetoclax if available unless contraindicated or clinically significant adverse effects are experienced.
Applicability	Applies to CLL/SLL, mantle cell lymphoma, multiple myeloma with t(11;14), and additional NCCN‑recommended off‑label indications when covered by this policy.
Exceptions	Use of brand may be allowed when generic venetoclax is contraindicated or when clinically significant adverse effects to generic formulation are documented.

Action	Notes / Policy implications
Consider therapeutic alternatives	Therapeutic alternatives listed in Appendix B should be considered; alternatives may be preferred or require prior authorization depending on line of business and formulary status.
Prior authorization justification	If therapeutic alternatives are available, prior authorization may require documentation or justification for selecting venetoclax over listed alternatives.
Appendix B content	Appendix B provides example regimens and preferred alternatives for indications such as SLL, mantle cell lymphoma, and multiple myeloma; refer to Appendix B for specific agents and regimens.

Quantity Limits & Packaging

venetoclax — product strengths and quantity guidance

Package strengthsTablets available in 10 mg, 50 mg, and 100 mg strengths.

Quantity limits guidanceDispense per prescribing schedule and package strengths; calculate total tablets based on ramp-up and maintenance dosing.

Administration routeOral tablets per prescribing instructions and indicated regimens (including 5-week ramp-up where applicable).

Site of Care

Note

Site of care — oral outpatient; infusional antibody combinations require infusion‑capable setting

Venetoclax is administered orally in outpatient settings; if used in combination with infusional monoclonal antibodies (e.g., obinutuzumab/Gazyva or rituximab), coordinate treatment in an infusion‑capable setting per the combination regimen.

Oral administration can occur at home or outpatient clinic
Combinations with infusional monoclonal antibodies require infusion‑capable setting and scheduling coordination

Background

Venetoclax (Venclexta) is an oral small‑molecule BCL‑2 inhibitor that targets the anti‑apoptotic B‑cell lymphoma 2 protein to promote cancer cell apoptosis. It is FDA‑approved for treatment of chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) and, in combination with hypomethylating agents or low‑dose cytarabine, for certain newly diagnosed acute myeloid leukemia (AML) patients who are older or ineligible for intensive induction chemotherapy.

Definitions

BCL-2 inhibitor / Venetoclax — indication summary

Drug class and generic nameVenetoclax (Venclexta) — a BCL-2 inhibitor used to treat select hematologic malignancies.

FDA-approved indicationsChronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); newly-diagnosed acute myeloid leukemia (AML) in combination with azacitidine, decitabine, or low‑dose cytarabine for certain older or unfit adults.

Use in combination regimensApproved in AML only in combination with azacitidine, decitabine, or low‑dose cytarabine; dosing limits vary by combination (400 mg/day with azacitidine/decitabine; 600 mg/day with low‑dose cytarabine).

B-cell lymphoma 2 protein (BCL-2) definition

DefinitionB-cell lymphoma 2 protein (BCL-2): an anti-apoptotic protein targeted by venetoclax.

Mechanism relevance

OpenPayer

Venetoclax (Venclexta) coverage and prior authorization